• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

gastric cancer

Talicia: Highly Effective Eradication Regimen for Helicobacter pylori
Posted inInfections, New Drugs, Oncology, Regulatory

Talicia: Highly Effective Eradication Regimen for Helicobacter pylori

June 5, 2022September 8, 2022

Combination drug invented by RedHill Biopharma will get rid of Helicobacter pylori infection in 90% of patients.

Gastric cancer.
Posted inOncology, Regulatory

Opdivo and Keytruda: First-line Immunotherapy for Gastric Cancer and Esophageal Cancer

April 20, 2021September 8, 2022

Nivolumab or pembrolizumab should be added to standard chemotherapy to prolong the life of patients with gastric, esophageal, and gastroesophageal junction cancers.

Bemarituzumab: Breakthrough in Gastric Cancer Treatment
Posted inClinical Trials, Oncology

Bemarituzumab: Breakthrough in Gastric Cancer Treatment

April 7, 2021September 8, 2022

A new and effective targeted therapy, being developed by Five Prime Therapeutics and Amgen, for a deadly cancer disease in the past decade.

BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News